SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Canagliflozin and Metformin Hydrochloride Tablets are used to treat type 2 diabetes mellitus
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
